• Blood Vessel Function in Adolescents and Women With Polycystic Ovary Syndrome

  NCT01615562

  TerminatedObservationalUpdated Dec 14, 2015
• Cardiovascular Risk Markers in Polycystic Ovary Syndrome (PCOS)

  NCT01195168

  CompletedObservationalUpdated Sep 6, 2010
• Evaluation of Endocrine and Metabolic Parameters in the New Diagnostic Phenotypes of Polycystic Ovary Syndrome

  NCT00784615

  Unknown statusObservationalUpdated Nov 19, 2008
• Markers and Calculation of Cardiovascular Risk in the Distinct Phenotypes of Polycystic Ovary Syndrome

  NCT01392781

  Unknown statusObservationalUpdated Jul 13, 2011
• The Study of Polycystic Ovary Syndrome(PCOS) With Gene and Questionnaire

  NCT01114659

  CompletedObservationalUpdated Jan 1, 2014
• REFUEL PCOS Study 1

  NCT05973175

  Unknown statusObservationalUpdated Apr 17, 2024

ClinicalTrials.gov ID

NCT05410834

Lead Sponsor

Canadian Medical and Surgical Knowledge Translation Research GroupOTHER

Overall Status

Unknown status

Study Type

Observational

Enrollment

30Estimated

Last Update Posted

Jun 8, 2022Actual

Start Date

Jun 2022Estimated

Primary Completion Date

Feb 2023Estimated

Completion Date

Apr 2023Estimated

Official Title

The Characterization of Pro-vascular Regenerative Cell Exhaustion in Women With Polycystic Ovarian Syndrome

Brief Summary

PCOS-RCE is an observational, cross-sectional, two-arm study that is aimed at determining if an established diagnosis of polycystic ovarian syndrome (PCOS) influences the number of blood vessel-forming stem cells in the bloodstream. Circulating progenitor cells will be enumerated and the distribution patterns of these cell types will be assessed to determine if these parameters differ between individuals with PCOS and individuals without PCOS. Specifically, this study will evaluate if differential regenerative cell exhaustion (RCE) may account, at least in part, for the differences in cardiovascular risk reported between individuals with a diagnosis of PCOS and those without.

Detailed Description

Individuals with polycystic ovarian syndrome (PCOS) have been reported to be at higher risk of cardiovascular disease when compared to those without PCOS. While differential environmental exposures and genetic morphometries are believed to account in part for the difference, there is growing evidence that cardiometabolic risk factors can accelerate pro-vascular progenitor cell depletion and dysfunction. The cumulative effects that aberrant regenerative cell exhaustion (RCE) have on vessel repair accordingly increases the risk of atherothrombotic events.

PCOS-RCE is an observational, cross-sectional, two-arm study that will evaluate the progenitor cell profiles of peripheral blood samples from 30 individuals (15 with PCOS, 15 without PCOS). The working hypothesis is that individuals with PCOS have innately different progenitor cell profiles that can be further altered by their environment and genotype. The resultant differences in RCE capability will affect the balance between pro-inflammatory and vessel repair functions that, in turn, contribute to the contrasting cardiometabolic risks exhibited between the two study cohorts.

• Polycystic Ovary Syndrome

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

Female

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

• Capable and willing to provide informed consent

• Females aged 30 and above

• Must meet criteria for one of the following two groups:

  1. Documented diagnosis of PCOS OR
  2. Normal and regular menstrual cycles with no known diagnosis of PCOS

Exclusion Criteria:

• Menopause, as defined by 12 months of amenorrhea
• Known causes of irregular menstrual bleeding caused by conditions other than PCOS
• Known secondary causes of ovulatory dysfunction and/or hyperandrogenism
• Current pregnancy, active lactation, or less than 6 months postpartum
• Ongoing treatment with ovulation-inducing medication
• History of hysterectomy and/or bilateral oophorectomy
• Severe congestive heart failure (as defined by New York Heart Association - class IV)
• Any life-threatening disease expected to result in death within the next 2 years
• Any malignancy not considered cured. A subject is considered cured if there has been no evidence of cancer recurrence for the 5 years prior to screening.
• Known severe liver disease
• Known acquired immunodeficiency syndrome such as HIV
• Current treatment with systemic or oral corticosteroid therapy or other immunosuppressive agents
• Known autoimmune disorder (exception: type 1 diabetes)
• Active infectious disease requiring antibiotic or anti-viral agents

Observational Model

Case-Control

Time Perspective

Cross-Sectional

Lead Sponsor

Canadian Medical and Surgical Knowledge Translation Research GroupOTHER

9058568086